Skip to main content

ABCL AbCellera Biologics Inc.

Healthcare

12.55

Close 10/9

P/B
4.3
Loading candles…

Is AbCellera Biologics Inc. a buy? Fundamentals and valuation first

As of 2026-10-09

Growth: Good, Momentum: Strong; Valuation: Pricey, Quality: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Pricey.
TTM P/E -23.24 N/A
Price / book 4.29 78th percentile Pricey
Free-cash-flow yield (%) -4.66 30th percentile Average
Quality Weak ROE, TTM is Average; Operating margin, TTM is Lagging.
ROE, TTM (%) -18.38 25th percentile Average
Operating margin, TTM (%) -340.25 8th percentile Lagging
FCF margin, TTM (%) -271.19 8th percentile Lagging
Growth Good Revenue growth, TTM YoY is Top; Diluted EPS growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 101.28 92th percentile Top
Diluted EPS growth, TTM YoY (%) -3.57 54th percentile Good
Momentum Strong All 2 indicators are Top.
60-day return (%) 103.73 99th percentile Top
240-day return (%) 121.73 96th percentile Top
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Lagging.
20-day dollar volume 73,010,483 84th percentile Top
60-day annualized volatility (%) 104.54 85th percentile Lagging

AbCellera Biologics Inc. (ABCL) today

1 quant signals active · As of 2026-10-09

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

AbCellera Biologics Inc. (ABCL) peers and tracking

Watchlist

This page refreshes daily after the close. Add AbCellera Biologics Inc. to your watchlist to track signal changes on your next visit.

AbCellera Biologics Inc. (ABCL) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 99.49%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

6 historical occurrences (since 2022-07-19)
Average forward return after Top-quintile 6-month momentum。20-day: Win 83.3%, Sample 6, Median +15.44%, Excess +24.98%, Beat mkt rate 83.3%；60-day: Win 60%, Sample 5, Median +12.91%, Excess +24.38%, Beat mkt rate 80%

60 days after: historical avg +25.47%

20-day +27.37%
60-day +25.47%
20-day
60-day
Win
83.3%
60%
Sample
6
5
Median
+15.44%
+12.91%
Excess
+24.98%
+24.38%
Beat mkt rate
83.3%
80%

Over 5 occurrences, 60-day forward avg gained 25.47%, beat the market by 24.38 pts; win rate 60%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.23%, a 57.8% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

11 times historically; 60-day forward avg +16.63%, win rate 54.5%, beating the market by +11.3 pts on average.

Continue researching AbCellera Biologics Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.